Jiangsu, China

Chao Luan


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:

goldMedal1 out of 832,680 
Other
 patents

Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Chao Luan in Biopharmaceuticals

Introduction

Chao Luan is a notable inventor based in Jiangsu, China, recognized for his significant contributions to the field of biopharmaceuticals. His work primarily focuses on the application of PCSK9 inhibitors in the treatment of inflammatory immune diseases. With a patent portfolio that includes 1 patent, Luan's research has the potential to impact the treatment landscape for various immune-related conditions.

Latest Patents

Luan's most recent patent is titled "Application of PCSK9 inhibitors in the preparation of drugs for the treatment of inflammatory immune diseases." This invention explores the role and mechanism of PCSK9 in inflammatory immune diseases, particularly its application in developing drugs mediated by T cells. The patent highlights the use of PCSK9 monoclonal antibodies, PCSK9 interference RNA, and PCSK9 small molecule inhibitors for treating conditions such as psoriasis, atopic dermatitis, and urticaria. The findings suggest that PCSK9 plays a crucial role in managing inflammatory immune diseases, offering a pathway for treatments with fewer adverse reactions and improved efficacy.

Career Highlights

Throughout his career, Chao Luan has demonstrated a commitment to advancing medical science through innovative research. His work on PCSK9 inhibitors showcases his ability to bridge the gap between basic research and practical applications in drug development. Luan's contributions are paving the way for new therapeutic options that could significantly enhance patient care in the realm of inflammatory diseases.

Collaborations

Chao Luan has collaborated with esteemed colleagues, including Min Chen and Rong Yuan, to further his research endeavors. These partnerships have fostered a collaborative environment that enhances the quality and impact of their work in the biopharmaceutical sector.

Conclusion

Chao Luan's innovative research in the application of PCSK9 inhibitors represents a significant advancement in the treatment of inflammatory immune diseases. His contributions are expected to lead to more effective and safer therapeutic options for patients suffering from these conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…